Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Gastroenterology | Family Medicine
Vomiting Clinical Trials
A listing of Vomiting medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
California
Orange : Call for Information (Investigational Site 0014)
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Palm Springs : Call for Information (Investigational Site 0021)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Colorado
Aurora : Call for Information (Investigational Site 0001)
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
District of Columbia
Washington : Call for Information (Investigational Site 0041)
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Florida
Hialeah : Call for Information (Investigational Site 0026)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Jupiter : Call for Information (Investigational Site 0174)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Lakeland : Call for Information (Investigational Site 0035)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Miami : Call for Information (Investigational Site 0042)
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
St. Petersburg : Call for Information (Investigational Site 0012)
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Indiana
Anderson : Call for Information (Investigational Site 9277)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Evansville : Call for Information (Investigational Site 0020)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Indianapolis : Indiana University Melvin and Bren Simon Cancer Center
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Iowa
Cedar Rapids : Call for Information (Investigational Site 0037)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Kentucky
Louisville : Call for Information (Investigational Site 0003)
A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)
Maryland
Baltimore : Call for Information (Investigational Site 0034)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Rockville : Call for Information (Investigational Site 0036)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Massachusetts
Boston : Call for Information (Investigational Site 0020)
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Boston : Call for Information (Investigational Site 0013)
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Waltham : TESARO Inc
A Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy
Waltham : TESARO Inc
A Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy
Waltham : TESARO Inc
Phase 3 Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy
View More »
Worcester : Call for Information (Investigational Site 0175)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Missouri
St. Louis : Call for Information (Investigational Site 0043)
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
New York
Bronx : Children's Hospital at Montefiore
A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer
North Carolina
Durham : Duke University Medical Center
Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis
Pennsylvania
Philadelphia : University of Pennsylvania
Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain
South Carolina
Columbia : Call for Information (Investigational Site 0031)
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Tennessee
Nashville : Call for Information (Investigational Site 0022)
A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)
Texas
Houston : Call for Information (Investigational Site 0176)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Houston : UT MD Anderson Cancer Center
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
Temple : Scott and White Healthcare
Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients
Washington
Seattle : Call for Information (Investigational Site 0032)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Spokane : Providence Sacred Heart Medical Center and Children's Hospital
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
Tacoma : Call for Information (Investigational Site 9315)
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Argentina
Buenos Aires : Merck Sharp & Dohme (Argentina) Inc.
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Buenos Aires : Merck Sharp & Dohme (Argentina) Inc.
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Australia
Adelaide SA : RAH Cancer Centre, Royal Adelaide Hospital
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
South Granville : Merck Sharp & Dohme/Australia
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Austria
Vienna : Merck, Sharp & Dohme Ges.m.b.H.
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)
Brazil
Sao Paulo : MSD
A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)
Sao Paulo : MSD
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Bulgaria
Sofia : Merck Sharp & Dohme Bulgaria EOOD
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Canada
Kirkland : Merck Frosst Canada Ltd.
Fosaprepitant (EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030 AM1)
Chile
Santiago : Merck Sharp & Dohme (I.A.) Corp.
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Colombia
Bogota : MDS Colombia SAS
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Bogota : MDS Colombia SAS
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Czech Republic
Praha : Merck Sharp and Dohme s.r.o.
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Denmark
Aarhus : Department of Oncology
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Copenhagen : Rigshospitalet, Finsen Centret
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Glostrup : Merck Sharp & Dohme
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Herlev : Herlev Hospital
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Odense : Department of Oncology, Odense University Hospital
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Dominican Republic
Santo Domingo : MSD CARD
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Ecuador
Quito : MSD Ecuador
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Finland
Espoo : MSD Finland Oy
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
France
Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Germany
Berlin : Vivantes Klinikum Neukolln
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Haar : MSD Sharp & Dohme GMBH
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Haar : MSD Sharp & Dohme GMBH
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Kiel : Universitatsklinikum Schleswig Holstein
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Greece
Alimos : Vianex, S.A. / MSD
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Alimos : Vianex, S.A. / MSD
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Hungary
Budapest : MSD Pharma Hungary Kft.
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Budapest : MSD Pharma Hungary Kft.
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Budapest : MSD Pharma Hungary Kft.
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)
India
New Delhi : Dr. BRA IRCH, AIIMS
Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
Israel
Hod Hasharon : Merck Sharp & Dohme Co. Ltd.
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Hod Hasharon : Merck Sharp & Dohme Co. Ltd.
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Italy
Milan : MSD Italia S.r.l..
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Milan : MSD Italia
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Japan
Hidaka : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Kashihara : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Kashiwa : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Koshigaya : Research Site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Kyoto : Research
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
View More »
Maebashi : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Nagoya : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Nakagami : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Niigata : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Ota : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Sagamihara : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Sapporo : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Sayama : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Tokyo : Reseach site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Tokyo : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Yamagata : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Yokohama : Research site
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Korea, Republic of
Seoul : MSD Korea Ltd.
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225 AM1) (KMEC)
Seoul : Seoul St. Mary's Hospital
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)
Seoul : Samsung Medical Center
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)
Seoul : Kangpook Samsung Hospital
Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting
Seoul : Sangye Bahk Hospital, Inje School of Medicine
Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting
View More »
Seoul : Bungdang Seoul National University Hospital
Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting
Seoul : Samsung Medical Center
Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting
Latvia
Riga : Merck Sharp & Dohme Latvija SIA
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Lithuania
Vilnius : UAB "Merck Sharp & Dohme"
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Mexico
Mexico City : MSD
A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)
Mexico City : MSD
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Mexico City : MSD
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Netherlands
Haarlem : Merck Sharp & Dohme BV
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Haarlem : Merck Sharp & Dohme BV
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Norway
Drammen : MSD (Norge) AS
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Drammen : MSD (Norge) AS
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Oslo : The Norwegian Radium Hospital
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Peru
Lima : Merck Sharp & Dohme, Peru S.R.L.
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Lima : Merck Sharp & Dohme, Peru S.R.L.
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Lima : Merck Sharp & Dohme, Peru S.R.L.
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Poland
Warszawa : MSD Polska Sp. Z o.o.
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Warszawa : MSD Polska Sp. Z o.o.
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Warszawa : MSD Polska Sp. Z o.o.
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Portugal
Paco D`arcos : Merck Sharp & Dohme Lda.
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Paco D`arcos : Merck Sharp & Dohme Lda.
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)
Russian Federation
Moscow : Merck Sharp & Dohme IDEA, Inc.
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Slovenia
Ljubljana : Merck Sharp & Dohme Idea, Inc
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Spain
Madrid : Merck Sharp and Dohme de Espana S.A.
A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)
Madrid : Merck Sharp and Dohme de Espana S.A.
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Madrid : Merck Sharp and Dohme de Espana S.A.
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Madrid : Merck Sharp and Dohme de Espana S.A.
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Madrid : Merck Sharp and Dohme de Espana S.A.
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)
Sweden
Sollentuna : MSD
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Sollentuna : MSD
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
Sollentuna : MSD
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Switzerland
Glattbrugg : MSD Merck Sharp & Dohme AG
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Thailand
Bangkok : MSD (Thailand) Ltd.
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-induced Nausea and Vomiting (MK-0517-031 AM3)
Turkey
Istanbul : Merck Sharp & Dohme Ilaclari Ltd. Sti
A Study of Aprepitant (MK0869) in Pediatric Participants Undergoing Surgery (0869-148 AM1)
Istanbul : Merck Sharp & Dohme Ilaclari Ltd. Sti
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)
United Kingdom
Hoddesdon : Merck Sharp & Dohme Ltd.
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3)